Ellagic acid reveals promising anti-aging effects against D-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study

Rahimi, V. B. and Askari, V. R. and Mousavi, S. H. (2018) Ellagic acid reveals promising anti-aging effects against D-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study. Biomedicine and Pharmacotherapy, 108. pp. 1712-1724.

[img] Text
Ellagic acid reveals promising anti-aging effects against D-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y A mechanistic study.pdf

Download (2MB)

Abstract

Background: Aging is a progressive, accumulative and natural phenomenon that leads to irreversible changes in all molecules, cells, tissues and organs of an organism. Previous studies have demonstrated that D-galactose (DG) imitates human natural aging. EA has also shown many pharmacological properties including anti-inflammatory and anti-oxidant activities. Methods: In the present study, we are aimed to evaluate anti-aging effects of EA (0.01–10 μM) on DG-induced aging model in SH-SY5Y human neuroblastoma cells, using assessment of cell proliferation, lipid peroxidation (MDA), intra-cellular reactive oxygen species (ROS), inflammation (TNF-α), total glutathione content (GSH), Beta-Galactosidase (β-GAL) and advanced glycation end products (AGEs) levels. Furthermore, the effects of EA were examined on HO-1 or PPAR-γ pathways using their selective inhibitors ZnPP or GW9662, respectively. Results: The results revealed that EA (0.01–10 μM) significantly increased cell proliferation and GSH level, while decreased the levels of ROS, MDA, TNF-α β-GAL and AGEs following DG-induced aging. Our findings also presented that pre-incubation with ZnPP exacerbates toxicity features of DG-induced aging in all measured parameters. Furthermore, we showed that pre-incubation of EA (0.1 and 1 μM) with either GW9662 or ZnPP significantly prevents the protective activities on cell proliferation, ROS, MDA, GSH and TNF-α levels following DG-induced aging (p < 0.001 for all cases). Additionally, EA (0.1 and 1 μM) along with GW9662 did not affect the levels of β-GAL and AGES in comparison to DG-induced aging group. Conclusion: Although we described for the first time that EA at low concentrations (0.1–1 μM) provides greater antiaging properties than both its high concentration (10 μM) and metformin (2.5 mM) probably through PPAR-γ/HO-1 signaling pathway, but additional and deeper investigations are needed to show exact involving mechanisms. It could be suggestible that EA may be as anti-aging agent at low concentrations for age-related neurological disorders such as Parkinson's and Alzheimer's diseases. © 2018

Item Type: Article
Additional Information: Cited By :4 Export Date: 16 February 2020 CODEN: BIPHE Correspondence Address: Mousavi, S.H.; Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical SciencesIran; email: mousavih@mums.ac.ir
Uncontrolled Keywords: Aging Anti-inflammatory D-Galactose Ellagic acid Metformin PPAR-γ advanced glycation end product beta galactosidase galactose glutathione malonaldehyde peroxisome proliferator activated receptor gamma reactive oxygen metabolite tumor necrosis factor 2-chloro-5-nitrobenzanilide anilide mannitol protoporphyrin protoporphyrin zinc antiaging effect Article cell aging cell proliferation controlled study drug effect human human cell in vitro study inflammation lipid peroxidation neuroblastoma cell priority journal SH-SY5Y cell line chemistry metabolism neuroblastoma pathology tumor cell line Anilides beta-Galactosidase Cell Line, Tumor Cellular Senescence Glycation End Products, Advanced Humans Malondialdehyde Protoporphyrins Reactive Oxygen Species Tumor Necrosis Factor-alpha
Subjects: WT Geriatrics . Chronic Diseases
QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 06 May 2020 13:15
Last Modified: 06 May 2020 13:15
URI: http://eprints.mums.ac.ir/id/eprint/17476

Actions (login required)

View Item View Item